Thermo Fisher Scientific Inc. (TMO) Earnings Call Transcripts

Thermo Fisher Scientific Inc.'s Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, Thermo Fisher Scientific Inc. reported strong financial results, with revenue of $11.99 billion, representing a 10% year-over-year increase, and adjusted earnings per share (EPS) of $6.03, up 13%. Management raised full-year guidance for revenue to a range of $47.4 billion to $48.1 billion and adjusted EPS to $24.93 to $25.33, reflecting robust customer activity and operational performance. The company's growth strategy appears to be resonating well, leading to increased share gains across various end markets.

Reported metrics

Guidance from management

Management raised full-year revenue guidance to $47.4 billion to $48.1 billion and adjusted EPS guidance to $24.93 to $25.33, reflecting strong operational performance and increased customer activity.

What management said

Yes, Mike, thanks for the question. So we look at it, we grew 3% in the first half, and we're stepping it up to 4% in the second half, and that includes a modest improvement to the outlook for the second half. And right now, we've outlined the way we see the quarterly phasing playing out, which is really not meaningfully changed versus our original assumption.

Yes, Dan, I wouldn't reach that assumption. We've been saying all along the second half steps up versus the first half. First half was low single-digit growth, and then it steps up meaningfully in the second half. It's all aligned to production schedules and with customer campaigns. -- but it doesn't necessarily imply that this fourth quarter grows over the third quarter.

What analysts pressed on

Analysts expressed concerns about the stability of the Academic and Government market, as well as the potential impact of the microbiology business divestiture on future revenue. There were questions regarding the timing of revenue recognition from recent authorizations in the clinical research segment.

Main topics on the call

• Revenue Growth Acceleration — Thermo Fisher achieved a revenue growth of 10% year-over-year, totaling $11.99 billion, exceeding previous guidance by approximately $300 million. CEO Marc Casper noted, "Customer activity across our end markets continue...
• Increased Guidance — Management raised full-year revenue guidance to $47.4 billion to $48.1 billion, reflecting a 6% to 8% growth over 2025. Adjusted EPS guidance was also increased to $24.93 to $25.33, representing 9% to 11% growth, with CE...
• Strong Performance in Pharma and Biotech — The Pharma and Biotech segment delivered mid-single-digit growth, driven by strong performance in Bioproduction and Clinical Research. Casper highlighted, "We saw spending pick up" in these areas, indicating a positive t...
• Successful Acquisitions — The integration of the Clario acquisition is progressing smoothly, contributing positively to revenue and earnings. Casper mentioned, "The funnel of revenue synergies is building nicely," suggesting future growth potenti...

Read the full Thermo Fisher Scientific Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 80 Thermo Fisher Scientific Inc. earnings call transcripts on record, spanning January 14, 2020 to July 23, 2026. Based on this history, Thermo Fisher Scientific Inc. reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TMO

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

80

First call

January 14, 2020

Most recent

July 23, 2026

Reporting cadence

quarterly